A field guide to BPC-157The criteria
PRODUCT / CARE / COMMITMENT
Open the provider file

Research explained

BPC-157 in gentamicin-related kidney injury

The experiment does not establish prevention of antibiotic toxicity in patients.

On this page

Read the experiment

The finding and its boundary

The authors reported attenuation of renal injury and altered oxidative-stress and nitric-oxide measures. The experiment does not establish prevention of antibiotic toxicity in patients.

Stable pentadecapeptide therapy counteracts gentamicin-induced nephrotoxicity via nitric oxide-system modulation: evidence from a triple nitric oxide-agent approach in rats.

Experiment
Experimental animal investigation with the intervention and outcomes specified in the indexed abstract.
Study system
Rats exposed to a nephrotoxic gentamicin regimen
Measured outcome
Kidney biochemistry, urine output, tissue injury and NO-related measures
Reported result
The authors reported attenuation of renal injury and altered oxidative-stress and nitric-oxide measures.
What this cannot establish
The experiment does not establish prevention of antibiotic toxicity in patients.
Open the primary paper

What was actually tested

Rats exposed to a nephrotoxic gentamicin regimen. The investigators measured kidney biochemistry, urine output, tissue injury and NO-related measures. The authors reported attenuation of renal injury and altered oxidative-stress and nitric-oxide measures.

The detail that changes the takeaway

An interaction experiment using nitric-oxide modifiers can help examine mechanism. It does not determine whether adding an investigational peptide to a prescribed antibiotic is safe. Renal function during antibiotic care requires established monitoring, not an inferred protective combination.

How far the result travels

The experiment does not establish prevention of antibiotic toxicity in patients.

The drug-injury setting

A gentamicin toxicity model cannot be treated as a study of normal kidney aging, chronic kidney disease or prevention in otherwise healthy people. The CareFirst prescription-filling review concerns a different decision: what an outside prescription actually authorizes a pharmacy to prepare. That service does not supply the missing human kidney outcome. The evidence guide keeps the experimental finding distinct from that service agreement.

References & product documents

The evidence and service information used here.

  1. BPC-157 in gentamicin-related kidney injury — original indexed research

Next in the field guide

The provider file
  1. 01

    Can one BPC-157 study support the product in front of you?

    Match the claim, ingredient, route and outcome. A relevant paper can still leave the central purchasing question unanswered.

  2. 02

    CareFirst Specialty Pharmacy BPC-157 review: the outside prescription comes first

    A capsule listing cannot be substituted for an injection order or a consultation bundle.

  3. 03

    BPC-157 and alcohol-induced lesions: an injury model is not a recovery aid

    The 2018 rat experiment imposed a strong chemical injury. It does not establish protection from drinking alcohol or justify a peptide recovery product.

Before you leave

One more option to compare.

Another provider review

We may earn a commission from qualifying provider referrals. Affiliate placements are labeled Partner. How we are funded

Continue to your choiceRead another review